Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Tuesday’s analyst upgrades and downgrades Add to ...

Subscribers Only

Inside the Market’s roundup of some of today’s key analyst actions

Pershing Square’s decision to sell its entire investment in Valeant Pharmaceuticals International Inc. (VRX-N, VRX-T) sends an “untimely poor signal,” according to BMO Nesbitt Burns analyst Gary Nachman.

On Monday, Pershing, led by billionaire investor William Ackman, abruptly announced the sale of its entire stake for a loss of more than $3-billion (U.S.). At one time, Mr. Ackman had been one of Valeant’s most vocal defenders.

Report Typo/Error

Follow on Twitter: @daveleeder


More Related to this Story


Next story




Most popular videos »

More from The Globe and Mail

Most popular